Topical treatment of cutaneous vaccinia virus infections in immunosuppressed hairless mice with selected antiviral substances

Antiviral Chemistry and Chemotherapy

Volumn 21, Issue 5, 2011, Pages 201-208

  Smee, Donald F ^a   Bailey, Kevin W ^a   Wong, Min Hui ^a   Bart Tarbet, E ^a  

^a UTAH STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; CYCLOPHOSPHAMIDE; CYTARABINE; HYPOXANTHINE ARABINOSIDE; PHOSPHONOACETIC ACID; RIBAVIRIN; TARIBAVIRIN; VIDARABINE; 2 AMINO 7 [(1,3 DIHYDROXY 2 PROPOXY)METHYL]PURINE; ANTIVIRUS AGENT; CYTOSINE; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; PURINE DERIVATIVE;

ANIMAL MODEL; ANTIVIRAL THERAPY; ARTICLE; COMPARATIVE EFFECTIVENESS; CUTANEOUS VACCINIA VIRUS INFECTION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; FATALITY; FEMALE; HAIRLESS MOUSE; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SKIN DEFECT; SKIN INFECTION; TREATMENT DURATION; VACCINIA; VACCINIA VIRUS; ANIMAL; CHEMISTRY; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; TOPICAL DRUG ADMINISTRATION; VIRAL SKIN DISEASE; VIROLOGY;

ADMINISTRATION, TOPICAL; ANIMALS; ANTIVIRAL AGENTS; CYCLOPHOSPHAMIDE; CYTOSINE; FEMALE; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; MICE; MICE, HAIRLESS; MICROBIAL SENSITIVITY TESTS; PHOSPHONIC ACIDS; PURINES; SKIN DISEASES, VIRAL; VACCINIA; VACCINIA VIRUS;

EID: 80053305871     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1734     Document Type: Article

References (32)

1. Bossi P, Garin D, Guihot A, et al. Bioterrorism: management of major biological agents. Cell Mol Life Sci 2006; 63:2196-2212.
2. Kman NE, Nelson RN. Infectious agents of bioterrorism: A review for emergency physicians. Emerg Med Clin North Am 2008; 26:517-547.
3. Fulginiti VA, Papier A, Lane JM, Neff JM, Henderson DA. Smallpox vaccination: A review, part I. Background, vaccination technique, normal vaccination and revaccination, and expected normal reactions. Clin Infect Dis 2003; 37:241-250.
4. Bray M. Pathogenesis and potential antiviral therapy of complications of smallpox vaccination. Antiviral Res 2003; 58:101-114.
5. Vora S, Damon I, Fulginiti V, et al. Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin Infect Dis 2008; 46:1555-1561.
6. Neyts J, De Clercq E. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice. J Med Virol 1993; 41:242-246.
7. Bray M, Martinez M, Smee DF, Kefauver D, Thompson E, Huggins JW. Cidofovir (HPMPC) protects mice against lethal aerosol or intranasal cowpox virus challenge. J Infect Dis 2000; 181:10-19.
8. Smee DF, Bailey KW, Wong M-H, Wandersee MK, Sidwell RW. Topical cidofovir is more effective than parenteral therapy for treatment of progressive vaccinia in immunocompromised mice. J Infect Dis 2004; 190:1132-1139.
9. Quenelle DC, Collins DJ, Kern ER. Cutaneous infections of mice with vaccinia or cowpox viruses and efficacy of cidofovir. Antiviral Res 2004; 63:33-40.
10. Neyts J, Leyssen P, Verbeken E, De Clercq E. Efficacy of cidofovir in a murine model of disseminated progressive vaccinia. Antimicrob Agents Chemother 2004; 48:2267-2273.
11. Smee DF, Sidwell RW. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res 2003; 57:41-52.
12. Smee DF. Progress in the discovery of compounds inhibiting orthopoxviruses in animal models. Antivir Chem Chemother 2008; 19:115-124.
13. Smee DF, Sidwell RW. Anti-cowpox virus activities of certain adenosine analogs, arabinofuranosyl nucleosides, and 2'-fluoro-arabinofuranosyl nucleosides. Nucleosides Nucleotides Nucleic Acids 2004; 23:375-383.
14. Lin CC, Yeh LT, Vitarella D, Hong Z. Viramidine, a prodrug of ribavirin, shows better liver-targeting properties and safety profiles than ribavirin in animals. Antivir Chem Chemother 2003; 14:145-152.
15. Helgstrand E, Eriksson B, Johansson NG, et al. Trisodium phosphonoformate, a new antiviral compound. Science 1978; 201:819-821.
16. Toro JR, Wood LV, Patel NK, Turner ML. Topical cidofovir. A novel treatment for recalcitrant molluscum contagiosum in children infected with human immunodeficiency virus 1. Arch Dermatol 2000; 136:983-985.
17. Bischofberger N, Hitchcock MJ, Chen MS, et al. 1-[(S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl] cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine with improved therapeutic index in vivo. Antimicrob Agents Chemother 1994; 38:2387-2391.
18. Friedman-Kien AE, Fondak AA, Klein RJ. Phosphonoacetic acid treatment of Shope fibroma and vaccinia virus skin infections in rabbits. J Invest Dermatol 1976; 66:99-102.
19. Jolley WB, Pettis JL. Minimal effects of ribavirin on the immune system. In Smith RA, Kirkpatrick W (Editors). Ribavirin, a broad spectrum antiviral agent. New York: Academic Press 1980; pp. 73-81.
20. De Clercq E, Luczak M, Shugar D, Torrence PF, Waters JA, Witkop B. Effect of cytosine arabinoside, iododeoxyuridine, ethyldeoxyuridine, thiocyanatodeoxyuridine, and ribavirin on tail lesion formation in mice infected with vaccinia virus. Proc Soc Exp Biol Med 1976; 151:487-490.
21. Smee DF, Bailey KW, Sidwell RW. Treatment of cowpox virus respiratory infections in mice with ribavirin as a single agent or followed sequentially by cidofovir. Antivir Chem Chemother 2000; 11:303-309.
22. Neyts J, De Clercq E. Efficacy of 2-amino-7-(1,3-dihydroxy-2-propoxymethyl)purine for the treatment of vaccinia virus (orthopoxvirus) infections in mice. Antimicrob Agents Chemother 2001; 45:84-87.
23. Smee DF, Bailey KW, Sidwell RW. Treatment of lethal cowpox virus respiratory infections in mice with 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine and its orally active diacetate ester prodrug. Antiviral Res 2002; 54:113-120.
24. Hyndiuk RA, Okumoto M, Damiano RA, Valenton M, Smolin G. Treatment of vaccinial keratitis with vidarabine. Arch Ophthalmol 1976; 94:1363-1364.
25. Sidwell RW, Allen LB, Huffman JH, Revankar GR, Robins RK, Tolman RL. Viral keratitis-inhibitory effect of 9-β-D-arabinofuranosylhypoxanthine 5'-monophosphate. Antimicrob Agents Chemother 1975; 8:463-467.
26. Sloan BJ. Adenine arabinoside: Chemotherapy studies in animals. In Pavan-Langston D, Buchanan RA, Alford CA, Jr (Editors). Adenine arabinoside: An antiviral agent. New York: Raven Press 1975; pp. 45-94.
27. Smee DF, Bray M, Huggins JW. Antiviral activity and mode of action studies of ribavirin and mycophenolic acid against orthopoxviruses in vitro. Antivir Chem Chemother 2001; 12:327-335.
28. Leinbach SS, Reno JM, Lee LF, Isbell AF, Boezi JA. Mechanism of phosphonoacetate inhibition of herpes virusinduced DNA polymerase. Biochemistry 1976; 15:426-430.
29. Overby LR, Duff RG, Mao JC. Antiviral potential of phosphonoacetic acid. Ann N Y Acad Sci 1977; 284:310-320.
30. Spruance SL, McKeough MB, Cardinal JR. Penetration of guinea pig skin by acyclovir in different vehicles and correlation with the efficacy of topical therapy of experimental cutaneous herpes simplex virus infection. Antimicrob Agents Chemother 1984; 25:10-15.
31. Spruance SL, McKeough M, Sugibayashi K, Robertson F, Gaede P, Clark DS. Effect of azone and propylene glycol on penetration of trifluorothymidine through skin and efficacy of different topical formulations against cutaneous herpes simplex virus infections in guinea pigs. Antimicrob Agents Chemother 1984; 26:819-823.
32. Sidwell RW, Huffman JH, Schafer TW, Shipman C. Influence of vehicle on topical efficacy of 2-acetylpyridine thiosemicarbazone and related derivatives on in vivo type 2 herpes simplex virus infections. Chemotherapy 1990; 36:58-69.